Shifting the Biosynthesis of Leukotrienes Toward Specialized Pro-Resolving Mediators by the 5-Lipoxygenase-Activating Protein (FLAP) Antagonist BRP-201.
leukotrienes
lipid mediators
lipoxygenase
specialized pro-resolving mediators
Journal
Journal of inflammation research
ISSN: 1178-7031
Titre abrégé: J Inflamm Res
Pays: New Zealand
ID NLM: 101512684
Informations de publication
Date de publication:
2022
2022
Historique:
received:
21
10
2021
accepted:
28
12
2021
entrez:
17
2
2022
pubmed:
18
2
2022
medline:
18
2
2022
Statut:
epublish
Résumé
Lipid mediators (LM) play crucial roles in the complex inflammation process with respect to initiation, maintenance, and resolution. Proinflammatory leukotrienes (LTs), generated by 5-lipoxygenase (LOX) and the 5-LOX-activating protein (FLAP), initiate and maintain inflammation while specialized pro-resolving mediators (SPMs) formed by various LOXs as key enzymes promote inflammation resolution and the return to homeostasis. Since 5-LOX also contributes to SPM biosynthesis, smart pharmacological manipulation of the 5-LOX pathway and accompanied activation of 12-/15-LOXs may accomplish suppression of LT formation but maintain or even elevate SPM formation. Here, we demonstrated that the FLAP antagonist BRP-201 possesses such pharmacological profile and causes a switch from LT toward SPM formation. Comprehensive LM metabololipidomics with activated human monocyte-derived macrophages (MDM) of M1 or M2 phenotype showed that BRP-201 strongly inhibits LT formation induced by bacterial exotoxins. In parallel, SPM levels and 12/15-LOX-derived products were markedly elevated, in particular in M2-MDM. Intriguingly, in unstimulated MDM, BRP-201 induced formation of 12/15-LOX products including SPM and caused 15-LOX-1 subcellular redistribution without affecting 5-LOX. Experiments with HEK293 cells stably expressing either 5-LOX with or without FLAP, 15-LOX-1 or 15-LOX-2 confirmed suppression of 5-LOX product formation due to FLAP antagonism by BRP-201 but activated 15-LOX-1 in the absence of FLAP. Finally, in zymosan-induced murine peritonitis, BRP-201 (2 mg/kg, ip) lowered LT levels but elevated 12/15-LOX products including SPMs. BRP-201 acts as FLAP antagonist but also as 12/15-LOX activator switching formation of pro-inflammatory LTs toward inflammation-resolving SPM, which reflects a beneficial pharmacological profile for intervention in inflammation.
Sections du résumé
BACKGROUND AND PURPOSE
OBJECTIVE
Lipid mediators (LM) play crucial roles in the complex inflammation process with respect to initiation, maintenance, and resolution. Proinflammatory leukotrienes (LTs), generated by 5-lipoxygenase (LOX) and the 5-LOX-activating protein (FLAP), initiate and maintain inflammation while specialized pro-resolving mediators (SPMs) formed by various LOXs as key enzymes promote inflammation resolution and the return to homeostasis. Since 5-LOX also contributes to SPM biosynthesis, smart pharmacological manipulation of the 5-LOX pathway and accompanied activation of 12-/15-LOXs may accomplish suppression of LT formation but maintain or even elevate SPM formation. Here, we demonstrated that the FLAP antagonist BRP-201 possesses such pharmacological profile and causes a switch from LT toward SPM formation.
METHODS AND RESULTS
RESULTS
Comprehensive LM metabololipidomics with activated human monocyte-derived macrophages (MDM) of M1 or M2 phenotype showed that BRP-201 strongly inhibits LT formation induced by bacterial exotoxins. In parallel, SPM levels and 12/15-LOX-derived products were markedly elevated, in particular in M2-MDM. Intriguingly, in unstimulated MDM, BRP-201 induced formation of 12/15-LOX products including SPM and caused 15-LOX-1 subcellular redistribution without affecting 5-LOX. Experiments with HEK293 cells stably expressing either 5-LOX with or without FLAP, 15-LOX-1 or 15-LOX-2 confirmed suppression of 5-LOX product formation due to FLAP antagonism by BRP-201 but activated 15-LOX-1 in the absence of FLAP. Finally, in zymosan-induced murine peritonitis, BRP-201 (2 mg/kg, ip) lowered LT levels but elevated 12/15-LOX products including SPMs.
CONCLUSION
CONCLUSIONS
BRP-201 acts as FLAP antagonist but also as 12/15-LOX activator switching formation of pro-inflammatory LTs toward inflammation-resolving SPM, which reflects a beneficial pharmacological profile for intervention in inflammation.
Identifiants
pubmed: 35173459
doi: 10.2147/JIR.S345510
pii: 345510
pmc: PMC8842732
doi:
Types de publication
Journal Article
Langues
eng
Pagination
911-925Informations de copyright
© 2022 Kretzer et al.
Déclaration de conflit d'intérêts
Professor Erden Banoglu reports grants from TUBITAK, during the conduct of the study. The authors declare no conflicts of interest in this work.
Références
J Clin Invest. 2018 Jul 2;128(7):2680-2690
pubmed: 30108195
Biochem Pharmacol. 2021 Nov;193:114759
pubmed: 34487716
Eur J Med Chem. 2018 Aug 5;156:815-830
pubmed: 30053720
Nat Chem Biol. 2020 Jul;16(7):783-790
pubmed: 32393899
Clin Pharmacol Ther. 2017 Aug;102(2):238-245
pubmed: 28378879
Mol Biosyst. 2012 Apr;8(5):1585-94
pubmed: 22446875
FASEB J. 2016 Jan;30(1):276-85
pubmed: 26396238
FASEB J. 2015 Dec;29(12):5029-43
pubmed: 26289316
Subcell Biochem. 2007;42:3-27
pubmed: 17612044
Expert Opin Ther Pat. 2017 May;27(5):607-620
pubmed: 28005436
Nature. 2014 Jun 5;510(7503):92-101
pubmed: 24899309
Essays Biochem. 2020 Sep 23;64(3):443-462
pubmed: 32885825
Biochim Biophys Acta. 2014 Sep;1840(9):2961-9
pubmed: 24905297
Cell Rep. 2020 Oct 13;33(2):108247
pubmed: 33053344
J Leukoc Biol. 2005 Oct;78(4):871-8
pubmed: 16033810
Chem Rev. 2011 Oct 12;111(10):5821-65
pubmed: 21942677
J Med Chem. 2016 May 12;59(9):4202-9
pubmed: 26290290
N Engl J Med. 2007 Nov 1;357(18):1841-54
pubmed: 17978293
Biomolecules. 2021 May 17;11(5):
pubmed: 34067705
Acta Pharm Sin B. 2021 Jun;11(6):1629-1647
pubmed: 34221873
Nat Rev Immunol. 2015 Aug;15(8):511-23
pubmed: 26139350
Eur J Med Chem. 2018 Jun 10;153:34-48
pubmed: 28784429
Science. 2001 Nov 30;294(5548):1871-5
pubmed: 11729303
Biotechnol Adv. 2018 Nov 1;36(6):1709-1723
pubmed: 29454981
Biochem Pharmacol. 2018 Dec;158:161-173
pubmed: 30315753
Pharmacol Res. 2021 May;167:105556
pubmed: 33812006
FASEB J. 2019 May;33(5):6140-6153
pubmed: 30735438
Nat Commun. 2018 Jan 4;9(1):59
pubmed: 29302056
Gene. 2015 Nov 15;573(1):1-32
pubmed: 26216303
Biochem Pharmacol. 2005 Aug 1;70(3):327-33
pubmed: 15907806
Biochem Pharmacol. 2019 Jul;165:263-274
pubmed: 30836057
Prog Lipid Res. 2018 Oct;72:55-74
pubmed: 30237084
Phys Chem Chem Phys. 2018 May 30;20(21):14785-14795
pubmed: 29780994
J Clin Invest. 2018 Jul 2;128(7):2657-2669
pubmed: 29757195
Biochim Biophys Acta. 2015 Apr;1851(4):422-32
pubmed: 25263946
Biochim Biophys Acta Mol Cell Biol Lipids. 2019 Jun;1864(6):772-783
pubmed: 30010011
Proc Natl Acad Sci U S A. 2014 Oct 7;111(40):14530-5
pubmed: 25246560
J Inflamm Res. 2021 Feb 03;14:253-263
pubmed: 33568930
Eur J Med Chem. 2018 Apr 25;150:876-899
pubmed: 29597170
Biochim Biophys Acta. 2015 Apr;1851(4):331-9
pubmed: 25152163
Essays Biochem. 2020 Sep 23;64(3):423-441
pubmed: 32808658
Bioorg Med Chem Lett. 2015 Jul 1;25(13):2607-12
pubmed: 26004579
Mol Aspects Med. 2017 Dec;58:12-20
pubmed: 28365269